Mesothelioma Risk to War Survivors Highlighted by Journalist’s Case
A new Italian case study highlights the mesothelioma risk to war survivors, including journalists and bystanders. In an article in BMJ Case Reports, researchers from Rome detail the case of a war journalist who contracted mesothelioma after more than ten years in the field. The male journalist worked in war zones in the Far and Near East. He inhaled a range of toxic substances including asbestos in the dust and smoke from destroyed buildings. The new case report is a sobering reminder that bombs and bullets are not the only deadly threats in war-torn regions. Asbestos dust poses an often-overlooked mesothelioma risk to war survivors. Asbestos and its Link to Mesothelioma Asbestos is a naturally-occurring mineral. It is inexpensive, plentiful, … Continue reading Mesothelioma Risk to War Survivors Highlighted by Journalist’s Case
Targeting Nerve Cells Might Offer New Way to Fight Mesothelioma, Other Cancers
Israeli scientists may have found a new way to fight mesothelioma and other cancers from the inside out by targeting nerve cells. Researchers at Technion – Israel Institute of Technology conducted the new study. It appears in the journal Science Advances. Nerve cells called neurons help promote tumor growth. The team reasoned that targeting these tumor nerve cells with a damaging drug might slow cancer progression. They tested the theory on triple-negative breast cancer tumors in mice. The tumors still grew but they grew much slower than the untreated tumors. The findings could have implications for other hard-to-treat cancers like malignant mesothelioma. New Options Needed for Malignant Mesothelioma Malignant mesothelioma is one of the rarest and most treatment-resistant cancers. Many … Continue reading Targeting Nerve Cells Might Offer New Way to Fight Mesothelioma, Other Cancers
CBD Oil for Mesothelioma? New Case Study Suggests It’s Possible
The case study of a UK lung cancer patient whose tumor shrunk while she was taking CBD oil could be a hopeful sign for mesothelioma patients, too. pleural mesothelioma and non-small cell lung cancer are different disease but they share many commonalities. Both affect the lungs and cause similar symptoms. Sometimes, a treatment that works for NSCLC can help mesothelioma patients and vice versa. The subject of the new case study was a lung cancer patient in her 80s. She went to the doctor for a cough that would not go away. A CT scan showed the woman had a tumor in her right lung. Later, she developed more lung tumors. The patient decided not to have surgery because of … Continue reading CBD Oil for Mesothelioma? New Case Study Suggests It’s Possible
Relapsed Mesothelioma Patients Live Longer on Opdivo in Phase 3 Trial
A multi-center British study suggests that the cancer drug Opdivo (nivolumab) may be a solid second-line treatment option for relapsed mesothelioma patients. The Phase-3 trial involved mesothelioma patients from 24 UK hospitals. All had an ECOG score of 0 or 1, meaning they were in reasonably good health overall. All of the patients had first-line treatment with platinum-based chemotherapy. Then their cancer came back. There is no approved treatment for relapsed mesothelioma patients. So these patients enrolled in the nivolumab trial. Although Opdivo is not a cure for mesothelioma, the results of the news trial show it could extend survival for the right patients. How Does Opdivo Work? Nivolumab is sold under the brand name Opdivo. It is an immunotherapy … Continue reading Relapsed Mesothelioma Patients Live Longer on Opdivo in Phase 3 Trial
Quinacrine for Mesothelioma? Anti-Malaria Drug May Help Patients with This Gene Mutation
Another study on quinacrine for mesothelioma suggests that the once-popular anti-malaria drug might help a subset of patients with a particular gene mutation. Quinacrine is sold under the brand name Atabrine. It used to be the main anti-malaria drug but most doctors now prefer chloroquine. Last fall, Penn State research on quinacrine for mesothelioma showed the drug has a “high degree of cytotoxicity” on its own. The newest study initially focused on the potential for synergistic effects of quinacrine and chemotherapy. It turns out that the drug can make cisplatin more lethal to mesothelioma cells. Further tests showed that cells with inactivated NF2 mutations were even more sensitive to quinacrine. As many as 60 percent of mesothelioma patients may have … Continue reading Quinacrine for Mesothelioma? Anti-Malaria Drug May Help Patients with This Gene Mutation
Access to Multi-Modality Mesothelioma Treatment Limited for Uninsured & Rural Residents
A new study shows a person’s insurance status and where they live often impact their access to multi-modality mesothelioma treatment. This can have an impact on their survival. Researchers at the University of Miami Sylvester Comprehensive Cancer Center conducted the new study. They shared their findings at the recent virtual world conference of the International Association for the Study of Lung Cancer. The study found that access to multi-modality mesothelioma treatment was more common in patients with private insurance or Medicare. It was also more common among those who lived closer to larger medical centers. People who lived further out or who did not have insurance often did not receive the treatments that offer the best odds of mesothelioma survival. … Continue reading Access to Multi-Modality Mesothelioma Treatment Limited for Uninsured & Rural Residents
Cancer-Fighting Gel Could “Change the Treatment Paradigm” for Mesothelioma
New National Cancer Institute research shows a cancer-fighting gel applied directly to the surface of a mesothelioma tumor could “change the treatment paradigm” for this troublesome cancer. NCI researchers in Maryland developed the treatment and tested it in animals with mesothelioma tumors. Their tests show mesothelioma tumors respond after just one application of the medication. The authors of a new report on the treatment say surgeons could use it to enhance mesothelioma surgery. They could even use the cancer-fighting gel on its own as a stand-alone therapy. The Challenge of Mesothelioma Tumor Shape Malignant mesothelioma is a surface malignancy. Surface malignancies are tumors that grow on the surface of other organs or tissues. In the case of mesothelioma, tumors occur … Continue reading Cancer-Fighting Gel Could “Change the Treatment Paradigm” for Mesothelioma
Second-Line Treatment with Ramucirumab Improves Mesothelioma Survival
New evidence suggests that second-line treatment with ramucirumab after first-line chemotherapy may lead to longer survival in people with pleural mesothelioma. Researchers in Italy recently published results of a double-blind, placebo-controlled trial of the drug. Ramucirumab inhibits a protein mesothelioma tumors need to form new blood vessels. The study included 161 pleural mesothelioma patients from across Italy. Researchers gave half of them second-line treatment with ramucirumab and another drug called gemcitabine. The other half had second-line treatment with gemcitabine alone. Results showed the ramucirumab group lived more than six months longer than those who got only gemcitabine. Few Options for Recurrent Mesothelioma Pleural mesothelioma is an aggressive cancer with few good treatment options. Most patients start with chemotherapy with Alimta. … Continue reading Second-Line Treatment with Ramucirumab Improves Mesothelioma Survival
Yervoy and Opdivo for Mesothelioma: Three Year Results Still Look Good
Three years after the last patients enrolled in the clinical trial of Yervoy and Opdivo for mesothelioma, survival results still look promising for this immunotherapy treatment. Researchers presented an update of the CheckMate 743 trial at the recent virtual conference of the European Society for Medical Oncology (ESMO). The team found that more than 23% of patients on Yervoy and Opdivo for mesothelioma were still alive at three years. Only 15% of the chemotherapy group were still living. Immunotherapy for Malignant Mesothelioma Alimta (pemetrexed) was the first drug to receive FDA approval for mesothelioma chemotherapy. The FDA approved it in 2004. Before Alimta, patients had even fewer options that they do today. Most mesothelioma patients now start treatment with a … Continue reading Yervoy and Opdivo for Mesothelioma: Three Year Results Still Look Good
Immune Checkpoint Inhibitor Safe Both Before and After Mesothelioma Surgery
A report presented to an international gathering of lung cancer doctors shows an immune checkpoint inhibitor can make pre-surgery chemotherapy more effective for pleural mesothelioma patients. The report was presented at the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer. The week-long virtual conference ended yesterday. Dr. Anne Tsao of the University of Texas MD Anderson Cancer Center presented her study results. They show that mesothelioma patients may benefit from an immune checkpoint inhibitor as part of neoadjuvant chemotherapy. The same drug may also be helpful as a maintenance therapy after surgery. How Does an Immune Checkpoint Inhibitor Work? Immune checkpoint inhibitors are a form of immunotherapy. Immunotherapy treatments work by manipulating the immune … Continue reading Immune Checkpoint Inhibitor Safe Both Before and After Mesothelioma Surgery
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."
Get your free copy of
“Surviving Mesothelioma” Today!